leadf
logo-loader
viewMedlab Clinical Ltd
(
ASX:MDC
)

Medlab Clinical signs deal to launch its nutraceuticals in Priceline Pharmacy

Along with Priceline, more than 2100 independent pharmacies will also be able to access Medlab’s nutraceutical range.

Priceline Pharmacy
The cannabis drug developer aims to help patients with diagnosed chronic diseases

Medlab Clinical Ltd (ASX:MDC) has signed an agreement with Australian Pharmaceutical Industries (API) to range Medlab’s nutraceuticals in Priceline Pharmacy, one of Australia’s biggest pharmacy groups.

As part of the agreement, API will also hold Medlab products in its warehouses, significantly expanding potential distribution to more than 2100 independent pharmacies who will now be able to easily access the product range.

READ: Medlab Clinical takes EMA and FDA approval track as cannabis research continues

The agreement positions Medlab’s nutraceutical range into professional pharmacy with onboarding expected to take 3-4 months.

It is anticipated these agreements will result in a substantial increase in sales in the 12-month period from official launch.

 

Medlab’s nutraceutical offering differs from general retail due to its exposure to clinical research and patents.

The company currently has 27 patents covering a large number of products in the nutraceutical range.

Included within the range are NanoCelle™ products which were developed using Medlab’s patented delivery platform.

READ: Medlab Clinical eyes cost savings following receipt of SME status in Europe

Medlab chief executive officer Dr Sean Hall said: “Medlab is very excited with this opportunity to work with Priceline Pharmacy and other independent groups as it allows us to support people in the community suffering chronic illnesses by providing them easier access to scientifically backed products via professional pharmacy.”

Medlab is expected to exhibit at this year’s largest pharmacy conference, APP on the Gold Coast in March.

Quick facts: Medlab Clinical Ltd

Follow
ASX:MDC

Price: 0.165 AUD

Market Cap: $56.46 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle...

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue generating partnering opportunities for its NanoCelle®...

on 24/6/21

2 min read